دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Too Little or Too Much? Extracellular Matrix Remodeling in Kidney Health and Disease
Sergi Clotet-Freixas and Ana Konvalinka
doi : 10.1681/ASN.2021050654
JASN July 2021, 32 (7) 1541-1543
Primacy in Kidney Allocation: Does It Alleviate the Barriers to Transplantation?
John S. Gill, Catherine R. Butler and Neil R. Powe
doi : 10.1681/ASN.2021040474
JASN July 2021, 32 (7) 1544-1545
New Kidney and Pancreas Allocation Policy: Moving to a Circle as the First Unit of Allocation
Ajay Israni, Andrew Wey, Bryn Thompson, Jon Miller, Vincent Casingal, Martha Pavlakis, Silke Niederhaus, Rachel Forbes, Amber Wilk, Warren McKinney, Raja Kandaswamy, Peter Stock and Jon Snyder
doi : 10.1681/ASN.2020121679
JASN July 2021, 32 (7) 1546-1550
Role of Platelets in Chronic Kidney Disease
Nishank Jain, Adam L. Corken, Amudha Kumar, Clayton L. Davis, Jerry Ware and John M. Arthur
doi : 10.1681/ASN.2020121806
JASN July 2021, 32 (7) 1551-1558
Platelet-dependent mechanisms for excessive clotting and bleeding in CKD remain undefined. Moreover, platelets’ contribution to inflammation, and specifically to CKD, are equally elusive. To date, descriptions of changes in the functional properties of circulating platelets during CKD have provided confusing interpretations. Experimental approaches that can advance our understanding of platelet dysfunction in CKD are needed, and studies that provide mechanistic insights into the dynamic relationships between thrombosis, bleeding, and inflammation associated with CKD will be essential to improve clinical management and outcomes for this vulnerable population. This article summarizes existing literature characterizing platelets in CKD and identifies areas that need further investigation.
Potential Therapeutic Targets for Cisplatin-Induced Kidney Injury: Lessons from Other Models of AKI and Fibrosis
Sophia M. Sears and Leah J. Siskind
doi : 10.1681/ASN.2020101455
JASN July 2021, 32 (7) 1559-1567
The effectiveness of cisplatin, a mainstay in the treatment of many solid organ cancers, is hindered by dose-limiting nephrotoxicity. Cisplatin causes AKI in 30% of patients. Patients who do not develop AKI by clinical standards during treatment are still at risk for long-term decline in kidney function and the development of CKD. The connection between AKI and CKD has become increasingly studied, with renal fibrosis a hallmark of CKD development. To prevent both the short- and long-term effects of cisplatin, researchers must use models that reflect both types of pathology. Although a lot is known about cisplatin-induced AKI, very little is known about the mechanisms by which repeated low levels of cisplatin lead to fibrosis development. In this review, strategies used in various rodent models to prevent kidney injury, its progression to fibrosis, or both, are examined to gain mechanistic insights and identify potential therapeutic targets for cisplatin-induced kidney pathologies. Reviewing the results from these models highlights the diverse and highly complex role of cell death, cell senescence, endoplasmic reticulum stress, autophagy, and immune cell activation in acute and chronic kidney injuries. The use of several models of kidney injury is needed for development of agents that will prevent all aspects of cisplatin-induced kidney injury.
Epidemiology and Outcomes of COVID-19 in Home Dialysis Patients Compared with In-Center Dialysis Patients
Caroline M. Hsu, Daniel E. Weiner, Gideon Aweh, Page Salenger, Doug S. Johnson and Eduardo Lacson
doi : 10.1681/ASN.2020111653
JASN July 2021, 32 (7) 1569-1573
SARS-CoV-2 Vaccine Acceptability in Patients on Hemodialysis: A Nationwide Survey
Pablo Garcia, Maria E. Montez-Rath, Heather Moore, Johnie Flotte, Chris Fults, Martha S. Block, Jialin Han, Mary Dittrich, Julie Parsonnet, Glenn M. Chertow, Geoffrey A. Block and Shuchi Anand
doi : 10.1681/ASN.2021010104
JASN July 2021, 32 (7) 1575-1581
Background Patients on dialysis are at increased risk for COVID-19–related complications. However, a substantial fraction of patients on dialysis belong to groups more likely to be hesitant about vaccination.
Platelet Function in CKD: A Systematic Review and Meta-Analysis
Constance C.F.M.J. Baaten, Marieke Sternkopf, Tobias Henning, Nikolaus Marx, Joachim Jankowski and Heidi Noels
doi : 10.1681/ASN.2020101440
JASN July 2021, 32 (7) 1583-1598
Background Patients with CKD are at high risk for thrombotic and hemorrhagic complications. Abnormalities in platelet function are central to these complications, but reports on platelet function in relation to CKD are conflicting, and vary from decreased platelet reactivity to normal or increased platelet responsiveness. The direct effects of uremic toxins on platelet function have been described, with variable findings.
Activation of Sympathetic Signaling in Macrophages Blocks Systemic Inflammation and Protects against Renal Ischemia-Reperfusion Injury
Sho Hasegawa, Tsuyoshi Inoue, Yasuna Nakamura, Daichi Fukaya, Rie Uni, Chia-Hsien Wu, Rie Fujii, Wachirasek Peerapanyasut, Akashi Taguchi, Takahide Kohro, Shintaro Yamada, Mikako Katagiri, Toshiyuki Ko, Seitaro Nomura, Atsuko Nakanishi Ozeki, Etsuo A. Susaki, Hiroki R. Ueda, Nobuyoshi Akimitsu, Youichiro Wada, Issei Komuro, Masaomi Nangaku and Reiko Inagi
doi : 10.1681/ASN.2020121723
JASN July 2021, 32 (7) 1599-1615
Background The sympathetic nervous system regulates immune cell dynamics. However, the detailed role of sympathetic signaling in inflammatory diseases is still unclear because it varies according to the disease situation and responsible cell types. This study focused on identifying the functions of sympathetic signaling in macrophages in LPS-induced sepsis and renal ischemia-reperfusion injury (IRI).
Empagliflozin Inhibits Proximal Tubule NHE3 Activity, Preserves GFR, and Restores Euvolemia in Nondiabetic Rats with Induced Heart Failure
Fl?vio A. Borges-J?nior, Dan?bia Silva dos Santos, Acaris Benetti, Juliano Z. Polidoro, Aline C.T. Wisnivesky, Renato O. Crajoinas, Ednei L. Antônio, Leonardo Jensen, Bruno Caramelli, Gerhard Malnic, Paulo J. Tucci and Adriana C.C. Girardi
doi : 10.1681/ASN.2020071029
JASN July 2021, 32 (7) 1616-1629
Background SGLT2 inhibitors reduce the risk of heart failure (HF) mortality and morbidity, regardless of the presence or absence of diabetes, but the mechanisms underlying this benefit remain unclear. Experiments with nondiabetic HF rats tested the hypothesis that the SGLT2 inhibitor empagliflozin (EMPA) inhibits proximal tubule (PT) NHE3 activity and improves renal salt and water handling.
Anti Human CX3CR1 VHH Molecule Attenuates Venous Neointimal Hyperplasia of Arteriovenous Fistula in Mouse Model
Sanjay Misra, Sreenivasulu Kilari, Binxia Yang, Amit Sharma, Chih-Cheng Wu, Roberto I. Vazquez-Padron and John Broadwater
doi : 10.1681/ASN.2020101458
JASN July 2021, 32 (7) 1630-1648
Background Fractalkine receptor 1 (CX3CR1) mediates macrophage infiltration and accumulation, causing venous neointimal hyperplasia (VNH)/venous stenosis (VS) in arteriovenous fistula (AVF). The effect of blocking CX3CR1 using an anti–human variable VHH molecule (hCX3CR1 VHH, BI 655088) on VNH/VS was determined using a humanized mouse in which the human CX3CR1 (hCX3CR1) gene was knocked in (KI).
3D Mapping Reveals a Complex and Transient Interstitial Matrix During Murine Kidney Development
Sarah N. Lipp, Kathryn R. Jacobson, David S. Hains, Andrew L. Schwarderer and Sarah Calve
doi : 10.1681/ASN.2020081204
JASN July 2021, 32 (7) 1649-1665
Background The extracellular matrix (ECM) is a network of proteins and glycosaminoglycans that provides structural and biochemical cues to cells. In the kidney, the ECM is critical for nephrogenesis; however, the dynamics of ECM composition and how it relates to 3D structure during development is unknown.
Serine Protease HTRA1 as a Novel Target Antigen in Primary Membranous Nephropathy
Laith Farah Al-Rabadi, Tiffany Caza, Claire Trivin-Avillach, Aylin R. Rodan, Nicole Andeen, Norifumi Hayashi, Brandi Williams, Monica P. Revelo, Fred Clayton, Jo Abraham, Edwin Lin, Willisa Liou, Chang-Jiang Zou, Nirupama Ramkumar, Tim Cummins, Daniel W. Wilkey, Issa Kawalit, Christian Herzog, Aaron Storey, Rick Edmondson, Ronald Sjoberg, Tianxin Yang, Jeremy Chien, Michael Merchant, John Arthur, Jon Klein, Chris Larsen and Laurence H. Beck
doi : 10.1681/ASN.2020101395
JASN July 2021, 32 (7) 1666-1681
Background Identification of target antigens PLA2R, THSD7A, NELL1, or Semaphorin-3B can explain the majority of cases of primary membranous nephropathy (MN). However, target antigens remain unidentified in 15%–20% of patients.
A Rare Autosomal Dominant Variant in Regulator of Calcineurin Type 1 (RCAN1) Gene Confers Enhanced Calcineurin Activity and May Cause FSGS
Brandon M. Lane, Susan Murray, Katherine Benson, Agnieszka Bierzynska, Megan Chryst-Stangl, Liming Wang, Guanghong Wu, Gianpiero Cavalleri, Brendan Doyle, Neil Fennelly, Anthony Dorman, Shane Conlon, Virginia Vega-Warner, Damian Fermin, Poornima Vijayan, Mohammad Azfar Qureshi, Shirlee Shril, Moumita Barua, Friedhelm Hildebrandt, Martin Pollak, David Howell, Matthew G. Sampson, Moin Saleem, Peter J. Conlon, Robert Spurney and Rasheed Gbadegesin
doi : 10.1681/ASN.2020081234
JASN July 2021, 32 (7) 1682-1695
Background Podocyte dysfunction is the main pathologic mechanism driving the development of FSGS and other morphologic types of steroid-resistant nephrotic syndrome (SRNS). Despite significant progress, the genetic causes of most cases of SRNS have yet to be identified.
Autonomous Calcium Signaling in Human and Zebrafish Podocytes Controls Kidney Filtration Barrier Morphogenesis
Lydia Djenoune, Ritu Tomar, Aude Dorison, Irene Ghobrial, Heiko Schenk, Jan Hegermann, Lynne Beverly-Staggs, Alejandro Hidalgo-Gonzalez, Melissa H. Little and Iain A. Drummond
doi : 10.1681/ASN.2020101525
JASN July 2021, 32 (7) 1697-1712
Background Podocytes are critical to maintaining the glomerular filtration barrier, and mutations in nephrotic syndrome genes are known to affect podocyte calcium signaling. However, the role of calcium signaling during podocyte development remains unknown.
Identification of an Altered Matrix Signature in Kidney Aging and Disease
Michael J. Randles, Franziska Lausecker, Qingyang Kong, Hani Suleiman, Graeme Reid, Maria Kolatsi-Joannou, Bernard Davenport, Pinyuan Tian, Sara Falcone, Paul Potter, Tom Van Agtmael, Jill T. Norman, David A. Long, Martin J. Humphries, Jeffrey H. Miner and Rachel Lennon
doi : 10.1681/ASN.2020101442
JASN July 2021, 32 (7) 1713-1732
Background Accumulation of extracellular matrix in organs and tissues is a feature of both aging and disease. In the kidney, glomerulosclerosis and tubulointerstitial fibrosis accompany the decline in function, which current therapies cannot address, leading to organ failure. Although histologic and ultrastructural patterns of excess matrix form the basis of human disease classifications, a comprehensive molecular resolution of abnormal matrix is lacking.
Patients with High Priority for Kidney Transplant Who Are Not Given Expedited Placement on the Transplant Waiting List Represent Lost Opportunities
Jesse D. Schold, Anne M. Huml, Emilio D. Poggio, John R. Sedor, Syed A. Husain, Kristin L. King and Sumit Mohan
doi : 10.1681/ASN.2020081146
JASN July 2021, 32 (7) 1733-1746
Background Kidney transplantation is associated with the best outcomes for most patients with ESKD. The national Kidney Allocation System prioritizes patients with Estimated Post-Transplant Survival (EPTS) scores in the top 20% for expedited access to optimal deceased donor kidneys.
Plasma Proteomics of Renal Function: A Transethnic Meta-Analysis and Mendelian Randomization Study
Pamela R. Mat?as-Garc?a, Rory Wilson, Qi Guo, Shaza B. Zaghlool, James M. Eales, Xiaoguang Xu, Fadi J. Charchar, John Dormer, Haifa Maalmi, Pascal Schlosser, Mohamed A. Elhadad, Jana Nano, Sapna Sharma, Annette Peters, Alessia Fornoni, Dennis O. Mook-Kanamori, Juliane Winkelmann, John Danesh, Emanuele Di Angelantonio, Willem H. Ouwehand, Nicholas A. Watkins, David J. Roberts, Agnese Petrera, Johannes Graumann, Wolfgang Koenig, Kristian Hveem, Christian Jonasson, Anna K?ttgen, Adam Butterworth, Marco Prunotto, Stefanie M. Hauck, Christian Herder, Karsten Suhre, Christian Gieger, Maciej Tomaszewski, Alexander Teumer, Melanie Waldenberger and Human Kidney Tissue Resource
doi : 10.1681/ASN.2020071070
JASN July 2021, 32 (7) 1747-1763
Background Studies on the relationship between renal function and the human plasma proteome have identified several potential biomarkers. However, investigations have been conducted largely in European populations, and causality of the associations between plasma proteins and kidney function has never been addressed.
Diagnosis, Education, and Care of Patients with APOL1-Associated Nephropathy: A Delphi Consensus and Systematic Review
Barry I. Freedman, Wylie Burke, Jasmin Divers, Lucy Eberhard, Crystal A. Gadegbeku, Rasheed Gbadegesin, Michael E. Hall, Tiffany Jones-Smith, Richard Knight, Jeffrey B. Kopp, Csaba P. Kovesdy, Keith C. Norris, Opeyemi A. Olabisi, Glenda V. Roberts, John R. Sedor and Erika Blacksher
doi : 10.1681/ASN.2020101399
JASN July 2021, 32 (7) 1765-1778
Background APOL1 variants contribute to the markedly higher incidence of ESKD in Blacks compared with Whites. Genetic testing for these variants in patients with African ancestry who have nephropathy is uncommon, and no specific treatment or management protocol for APOL1-associated nephropathy currently exists.
Phase 3 Randomized Study Comparing Vadadustat with Darbepoetin Alfa for Anemia in Japanese Patients with Nondialysis-Dependent CKD
Masaomi Nangaku, Kazuoki Kondo, Yoshimasa Kokado, Kiichiro Ueta, Genki Kaneko, Tsubasa Tandai, Yutaka Kawaguchi and Yasuhiro Komatsu
doi : 10.1681/ASN.2020091311
JASN July 2021, 32 (7) 1779-1790
Background Standard care for treating anemia in patients with CKD includes use of erythropoiesis-stimulating agents, which sometimes involves increased risks of cardiovascular morbidity and mortality. Previous studies in patients with anemia and nondialysis-dependent CKD (NDD-CKD) found significantly elevated hemoglobin levels with use of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, compared with placebo.
Effects of a Knowledge-Translation Intervention on Early Dialysis Initiation: A Cluster Randomized Trial
Navdeep Tangri, Amit X. Garg, Thomas W. Ferguson, Stephanie Dixon, Claudio Rigatto, Selina Allu, Elaine Chau, Paul Komenda, David Naimark, Gihad E. Nesrallah, Steven D. Soroka, Monica Beaulieu, Ahsan Alam, S. Joseph Kim, Manish M. Sood and Braden Manns
doi : 10.1681/ASN.2020091254
JASN July 2021, 32 (7) 1791-1800
Background The Initiating Dialysis Early and Late (IDEAL) trial, published in 2009, found no clinically measurable benefit with respect to risk of mortality or early complications with early dialysis initiation versus deferred dialysis start. After these findings, guidelines recommended an intent-to-defer approach to dialysis initiation, with the goal of deferring it until clinical symptoms arise.
The Effect of Tolvaptan on BP in Polycystic Kidney Disease: A Post Hoc Analysis of the TEMPO 3:4 Trial
Judith E. Heida, Ron T. Gansevoort, Vicente E. Torres, Olivier Devuyst, Ronald D. Perrone, Jennifer Lee, Hui Li, John Ouyang and Arlene B. Chapman
doi : 10.1681/ASN.2020101512
JASN July 2021, 32 (7) 1801-1812
Background The V2 receptor antagonist tolvaptan is prescribed to patients with autosomal dominant polycystic kidney disease to slow disease progression. Tolvaptan may alter BP via various acute and chronic effects.
Cardiac and Noncardiac Determinants of Exercise Capacity in CKD
Shanmugakumar Chinnappa, Nigel Lewis, Omer Baldo, Ming-Chieh Shih, Yu-Kang Tu and Andrew Mooney
doi : 10.1681/ASN.2020091319
JASN July 2021, 32 (7) 1813-1822
Background Impaired exercise capacity is a significant symptom of CKD and is associated with poor survival. Furthermore, there is a growing interest in applying exercise as a diagnostic tool or as therapy in CKD. However, an in-depth understanding of exercise physiology in CKD is still lacking.
High Incidence of Circuit Clotting in Critically Ill COVID-19 Patients Treated with Renal Replacement Therapy
Eloïse Grenon and Emmanuel Canet
doi : 10.1681/ASN.2021040528
JASN July 2021, 32 (7) 1823-1824
Utility of Phosphate Binder Equivalent Dose Concept
Manjunath Kulkarni
doi : 10.1681/ASN.2021040440
JASN July 2021, 32 (7) 1824
Authors’ Reply
Pablo E. Pergola, David P. Rosenbaum, Yang Yang and Glenn M. Chertow
doi : 10.1681/ASN.2021050606
JASN July 2021, 32 (7) 1824-1825
